Theravance Total Stockholder Equity vs Total Current Assets Analysis
TBPH Stock | USD 8.34 0.21 2.46% |
Theravance Biopharma financial indicator trend analysis is much more than just breaking down Theravance Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Theravance Biopharma is a good investment. Please check the relationship between Theravance Biopharma Total Stockholder Equity and its Total Current Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.
Total Stockholder Equity vs Total Current Assets
Total Stockholder Equity vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Theravance Biopharma Total Stockholder Equity account and Total Current Assets. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Theravance Biopharma's Total Stockholder Equity and Total Current Assets is 0.11. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Theravance Biopharma, assuming nothing else is changed. The correlation between historical values of Theravance Biopharma's Total Stockholder Equity and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Theravance Biopharma are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Stockholder Equity i.e., Theravance Biopharma's Total Stockholder Equity and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.11 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Theravance Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Theravance Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.As of now, Theravance Biopharma's Sales General And Administrative To Revenue is increasing as compared to previous years.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 293.0M | 130.5M | 110.7M | 105.2M | Cost Of Revenue | 7.3M | 6.6M | 6.1M | 5.7M |
Theravance Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Theravance Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Theravance Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 55.6M | 62.3M | 69.5M | 73.6M | 55.3M | 53.3M | |
Total Assets | 408.8M | 469.1M | 374.8M | 607.4M | 382.0M | 418.6M | |
Other Current Liab | 57.8M | 76.1M | 37.9M | (1.6M) | 24.8M | 40.9M | |
Total Current Liabilities | 111.7M | 123.6M | 58.6M | 28.7M | 24.8M | 23.5M | |
Other Liab | 28.0M | 2.2M | 2.7M | 91.5M | 105.2M | 110.5M | |
Accounts Payable | 4.8M | 6.8M | 3.1M | 1.6M | 1.5M | 1.4M | |
Other Assets | 6.1M | 3.3M | 4.1M | 201.9M | 232.2M | 243.8M | |
Inventory | 0.0 | 1.0 | 20.4M | 10.2M | 1.5M | 0.95 | |
Other Current Assets | 7.1M | 10.4M | 8.6M | 7.7M | 13.6M | 8.4M | |
Total Liab | 632.7M | 772.8M | 713.4M | 165.6M | 169.0M | 160.6M | |
Property Plant Equipment | 12.6M | 16.4M | 53.3M | 11.9M | 13.7M | 16.5M | |
Total Stockholder Equity | (223.8M) | (303.8M) | (338.6M) | 441.8M | 213.0M | 223.6M | |
Net Tangible Assets | (169.4M) | 116.7M | (338.6M) | 577.0M | 519.3M | 545.3M | |
Property Plant And Equipment Net | 59.2M | 59.7M | 53.3M | 52.0M | 45.4M | 33.1M | |
Current Deferred Revenue | 31.6M | 11.5M | 98K | 24K | (5.4M) | (5.2M) | |
Retained Earnings | (1.2B) | (1.5B) | (1.7B) | (853.9M) | (909.1M) | (954.6M) | |
Cash | 58.1M | 81.5M | 90.0M | 298.2M | 39.5M | 37.6M | |
Non Current Assets Total | 70.3M | 75.7M | 124.9M | 253.9M | 248.5M | 260.9M | |
Non Currrent Assets Other | 6.1M | 3.3M | 4.1M | 201.1M | 202.3M | 212.4M | |
Long Term Debt | 454.4M | 445.2M | 227.0M | 599.4M | 689.3M | 723.8M | |
Net Receivables | 50.6M | 69.7M | 57.6M | 16.8M | 17.5M | 27.9M | |
Short Term Investments | 222.8M | 211.5M | 83.5M | 29.3M | 62.9M | 112.2M | |
Liabilities And Stockholders Equity | 408.8M | 469.1M | 374.8M | 607.4M | 382.0M | 454.6M | |
Non Current Liabilities Total | 521.0M | 649.2M | 654.8M | 136.9M | 144.2M | 137.0M | |
Long Term Investments | 49.8M | 11.9M | 8.7M | 12.8M | 67.5M | 0.0 | |
Property Plant And Equipment Gross | 59.2M | 16.4M | 53.3M | 52.0M | 66.9M | 70.3M | |
Total Current Assets | 338.5M | 393.3M | 249.9M | 353.5M | 133.5M | 126.9M | |
Accumulated Other Comprehensive Income | 145K | 47K | 0.0 | (15K) | (65K) | (68.3K) | |
Net Debt | 434.9M | 565.6M | 562.1M | (224.1M) | 5.7M | 5.4M | |
Cash And Short Term Investments | 280.8M | 292.9M | 173.5M | 327.5M | 102.4M | 97.3M | |
Retained Earnings Total Equity | (1.2B) | (1.5B) | (1.7B) | (853.9M) | (768.5M) | (806.9M) | |
Capital Surpluse | 1.0B | 1.2B | 1.4B | 1.3B | 1.5B | 1.1B | |
Other Stockholder Equity | 1.0B | 1.2B | 1.4B | 1.3B | 1.1B | 1.1B | |
Non Current Liabilities Other | 21.3M | 1.8M | 2.7M | 1.7M | 33.7M | 35.4M | |
Short Long Term Debt Total | 492.9M | 647.1M | 652.1M | 74.1M | 45.2M | 43.0M | |
Long Term Debt Total | 454.4M | 445.2M | 227.0M | 228.0M | 262.2M | 330.2M |
Currently Active Assets on Macroaxis
MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce | |
MSFT | Microsoft | |
GOOG | Alphabet Inc Class C |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 1.191 | Quarterly Revenue Growth 0.392 | Return On Assets (0.06) | Return On Equity (0.16) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.